These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 25891736)

  • 1. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.
    Kawaoka T; Imamura M; Kan H; Fujino H; Fukuhara T; Kobayashi T; Honda Y; Naeshiro N; Hiramatsu A; Tsuge M; Hayes CN; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Tashiro H; Ohdan H; Chayama K
    Transplant Proc; 2015 Apr; 47(3):809-14. PubMed ID: 25891736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
    Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
    Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
    Sugimoto K; Kim SR; Kim SK; Imoto S; Tohyama M; Kim KI; Ohtani A; Hatae T; Yano Y; Kudo M; Hayashi Y
    Oncology; 2015; 89 Suppl 2():42-6. PubMed ID: 26584035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
    Kawaoka T; Imamura M; Morio K; Nakamura Y; Tsuge M; Nelson Hayes C; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Ohdan H; Chayama K
    Clin J Gastroenterol; 2017 Apr; 10(2):179-184. PubMed ID: 28224470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
    Zeuzem S; Buggisch P; Agarwal K; Marcellin P; Sereni D; Klinker H; Moreno C; Zarski JP; Horsmans Y; Mo H; Arterburn S; Knox S; Oldach D; McHutchison JG; Manns MP; Foster GR
    Hepatology; 2012 Mar; 55(3):749-58. PubMed ID: 22006408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.
    Forns X; Berenguer M; Herzer K; Sterneck M; Donato MF; Andreone P; Fagiuoli S; Cieciura T; Durlik M; Calleja JL; Mariño Z; Shukla U; Verbinnen T; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; Janssen K; Kalmeijer R; Jessner W
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28295849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil may induce prolonged severe anemia during pegylated-interferon/ribavirin/simeprevir therapy in liver transplant recipients.
    Kogiso T; Tokushige K; Hashimoto E; Taniai M; Omori A; Kotera Y; Egawa H; Yamamoto M; Shiratori K
    Clin J Gastroenterol; 2015 Jun; 8(3):156-61. PubMed ID: 25963122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation.
    Kawaoka T; Takahashi S; Tatsukawa Y; Hiramatsu A; Hiraga N; Miki D; Tsuge M; Imamura M; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Ide K; Tashiro H; Ohdan H; Chayama K
    Hepatol Res; 2014 Nov; 44(12):1259-64. PubMed ID: 24382214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
    Tanaka T; Sugawara Y; Akamatsu N; Kaneko J; Tamura S; Aoki T; Sakamoto Y; Hasegawa K; Kurosaki M; Izumi N; Kokudo N
    J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):144-50. PubMed ID: 25338946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.
    Werner CR; Egetemeyr DP; Lauer UM; Nadalin S; Königsrainer A; Malek NP; Berg CP
    Liver Transpl; 2012 Dec; 18(12):1464-70. PubMed ID: 22941516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
    El-Hamamsy M; Montasser IF; Mansy AE; Nabet DE; El-Meteini M
    J Clin Pharm Ther; 2019 Jun; 44(3):447-453. PubMed ID: 30714175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation.
    Miuma S; Ichikawa T; Miyaaki H; Haraguchi M; Tamada Y; Shibata H; Taura N; Soyama A; Hidaka M; Takatsuki M; Eguchi S; Nakao K
    J Interferon Cytokine Res; 2016 Jun; 36(6):358-66. PubMed ID: 27243278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
    Ogawa E; Furusyo N; Dohmen K; Kajiwara E; Kawano A; Nomura H; Takahashi K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J;
    J Viral Hepat; 2015 Dec; 22(12):992-1001. PubMed ID: 26075320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1.
    Nishida N; Iwanishi M; Minami T; Chishina H; Arizumi T; Takita M; Kitai S; Yada N; Ida H; Hagiwara S; Minami Y; Ueshima K; Sakurai T; Kitano M; Kudo M
    Dig Dis; 2015 Oct; 33(6):708-14. PubMed ID: 26488400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A; Serfaty L
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
    Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
    Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
    Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
    Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation.
    Ueda Y; Takada Y; Marusawa H; Egawa H; Uemoto S; Chiba T
    Transplantation; 2010 Sep; 90(6):661-5. PubMed ID: 20110853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
    Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
    Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.